Officials hope to increase the proportion of young adults buying plans before the March 31 open enrollment deadline.
About 2.2 million people have enrolled in health coverage through the federal and state exchange marketplaces and nearly a quarter of them are young adults, said Health and Human Services (HHS) secretary Kathleen Sebelius in a recent telephone briefing.
According to a new report, which details the first demographic information about enrollees, 24% of those that had signed up by the end of the third reporting period for open enrollment on Dec. 28, 2013 were between the ages of 18 and 34. A demographic often referred to as “young invincibles,” enrollment of young adults is vital to the long-term survival of the exchanges. In addition to those who have signed up for coverage through the exchanges, Sebelius says that about 3 million young adults have gained coverage through the Affordable Care Act's (ACA) provision which allows them to stay on their parents' plan until age 26.
The report also shows that enrollment in December was seven times greater than the combined total for the months of October and November, as well as eight times greater for young adults ages 18 to 34. More than 9 million people have gained coverage under the Affordable Care Act, officials now estimate.
While officials say they are satisfied with the numbers, they hope to increase the proportion of young adults buying plans before the March 31 open enrollment deadline. HHS spokeswoman Julie Bataille says administration outreach efforts would be widened over the next few months, and will include television advertising during Winter Olympic Games coverage in February.
A recent study by the Kaiser Family Foundation downplayed concerns that low enrollment of young adults might lead to a "death spiral." It stated that under a worst-case scenario in which only 25% of enrollees are age 18 to 34, insurers would have to raise premiums by 2.5% in 2015.
“There has been a lot of attention to the mix of individuals signing up for coverage so at the end of the day we have a balanced insurance pool,” says Mike Hash, director of the HHS Office of Health Reform. “The trend is suggestive of an appropriate mix in the marketplace. We are only halfway through and we expect an increase in the proportion of young adults as we go forward.”
Other key findings:
Of the enrollees:
Read the full report here.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More